In a report released on June 17, from Bank of America Securities maintained a Hold rating on Everest Medicines Ltd., with a price target of HK$...
Currently, the analyst consensus on Everest Medicines Ltd. is a Moderate Buy with an average price target of HK$52.73.
Based on Everest Medicines Ltd.’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of HK$223.06 million and a GAAP net loss of HK$124.9 million. In comparison, last year the company earned a revenue of HK$150.76 million and had a GAAP net loss of HK$316.21 million
Bank of America Securities analyst maintained a Buy rating on ASMPT Ltd on May 27 and set a price target of HK$310.00. The…
In a report released on May 27, Michael Toner CFA from RBC Capital maintained a Hold rating on Endeavour Group Ltd, with a price…
In a report released on June 25, from HSBC maintained a Hold rating on Knowledge Atlas Technology Joint Stock Company Limited…
In a report released on May 28, from Morgan Stanley maintained a Buy rating on Keymed Biosciences, Inc., with a price target of…
Canaccord Genuity analyst Andrew Hodge maintained a Hold rating on Bapcor Ltd today and set a price target of A$0.45.Claim 55%…
Citic Securities analyst maintained a Buy rating on Hesai Group Class B on May 28 and set a price target of HK$187.20. The…
